JMI Laboratories and bioMérieux Enter Antimicrobial Resistance Diagnostics Partnership
JMI Laboratories and bioMérieux will work to improve microbiology diagnostics tools.
JMI Laboratories, a microbiology laboratory owned by Element Materials Technology, and bioMérieux, a French biotechnology company specializing in diagnostics, announced a six-year partnership in an April 20, 2023 press release. The collaboration will aim to improve microbiology diagnostics in tools to fight antimicrobial resistance (AMR).
According to a company press release, Antimicrobial Stewardship Programs are dependent on rapid, reliable testing that must be continuously evaluated against new and emerging strains of global pathogens. In this partnership, bioMérieux will use data collected through JMI’s microbial surveillance tools to continuously assess AMR results.
“We are excited to partner with bioMérieux on these projects as we appreciate their commitment to improving patient care by providing accurate microbial identification and antimicrobial susceptibility testing results,” said Mariana Castanheira, chief scientific officer of JMI Labs, in the press release. “Our scientists look forward to managing these studies testing challenging organisms, including those carrying important mechanisms of resistance.”
“Through our combined efforts, we can proactively alert the scientific community of potential growing threats and effectively steer antimicrobial research and development,” said François Lacoste, executive vice-president, Research & Development, bioMérieux, in the release.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
